

CORRECTION

Open Access

Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition

Erika Hamilton¹, Kimberly Blackwell¹, Amy C Hobeika², Timothy M Clay³, Gloria Broadwater⁴, Xiu-Rong Ren⁵, Wei Chen⁵, Henry Castro³, Frederic Lehmann³, Neil Spector¹, Junping Wei⁶, Takuya Osada⁶, H Kim Lyerly² and Michael A Morse^{1*}

Corrections

In our original manuscript [1], the corresponding author, Michael A Morse, was missed from the authors' list. Therefore the correct author list should be:

Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, Timothy M Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frederic Lehmann, Neil Spector, Junping Wei, Takuya Osada, H Kim Lyerly and Michael A Morse.

Also the title of our original manuscript 'Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition' is also incorrect. The title should read: 'Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition'.

Journal of Translational Medicine regret any inconvenience that this inaccuracy might have caused.

Competing interests

The authors declare that they have no competing interests.

Authors' contribution

All authors read and approved the final manuscript.

Author details

¹Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA. ²Department of Surgery, Division of General Surgery, Duke University Medical Center, Durham, NC, USA. ³GlaxoSmithKline Biologicals, Rixensart, Belgium. ⁴Cancer Statistical Center, Duke Cancer Institute, Durham, NC, USA. ⁵Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA. ⁶Department of Surgery, Division of Surgical Sciences, Duke University Medical Center, Durham, NC, USA.

Received: 26 March 2013 Accepted: 26 March 2013

Published: 27 March 2013

Reference

1. Hamilton, et al: Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition. *J Transl Med* 2012, **10**:28.

doi:10.1186/1479-5876-11-82

Cite this article as: Hamilton et al.: Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition. *Journal of Translational Medicine* 2013 **11**:82.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



* Correspondence: michael.morse@duke.edu

¹Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA

Full list of author information is available at the end of the article